Biogen Stock – Fundamental Analysis
Price
243.93
11/5/2026
Fundamental Data & Ratios (Balance sheet update: 9/6/2026)
| Balance Sheet | Total Assets | 29,439,500,000.00 | Equity Ratio | 62.01 % |
| Balance Sheet | Total Equity | 18,256,800,000.00 | ROA | 4.39 % |
| Cashflow | Capital Expenditures | -153,800,000.00 | P/FCF | 17.45 |
| Cashflow | Free Cash Flow | 2,050,800,000.00 | – | – |
| Cashflow | Operating Cash Flow | 2,204,600,000.00 | P/CF | 16.23 |
| Income | Earnings per Share (diluted) | 8.79 | Div. Yield | – |
| Income | Net Income | 1,292,900,000.00 | P/E | 27.66 |
| Income | Shares Outstanding | 146,700,000.00 | P/B | 1.96 |
| Income | Total Revenue | 9,890,600,000.00 | P/S | 3.62 |
Ratios calculated on: 11/5/2026
Company Description
Biogen is a global biopharmaceutical company focused on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases.
Advanced Analysis Features
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.biogenidec.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more